Johnson & Johnson Statement on COVID-19 Vaccine Contract Disclosures

JOHANNESBURG, September 05, 2023 - Johnson & Johnson supported and worked closely with South Africa in every phase of our response to the pandemic. We supplied our vaccine to South Africa at our final global price of $7.50 per dose, transferred our technology to Aspen Pharmacare in Gqeberha to enable the local fill and finish of the Johnson & Johnson COVID-19 vaccine and later enabled Aspen to manufacture, market and sell its own COVID-19 vaccine, “Aspenovax.” In addition, we advocated for and supported the donation of hundreds of millions of vaccine doses by the U.S. Government, EU Member States, the United Kingdom, Canada and New Zealand to COVAX to under-resourced countries. To date, more than 85 percent of our doses have been delivered to low- and middle-income countries. 

We also ensured South Africa played a pivotal role in our clinical program and helped make our vaccine available to approximately 500,000 South African frontline healthcare workers via the Phase 3b SISONKE (“Together”) implementation study in early 2021.  

We remain deeply committed to helping address the health needs of people in South Africa.